The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review.

[1]  P. Gibbs,et al.  The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] , 2018, PloS one.

[2]  C. Tournigand,et al.  Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project , 2018, Journal of the National Cancer Institute.

[3]  A. Dupré,et al.  Inflammation and cancer: What a surgical oncologist should know. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  R. Labianca,et al.  Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. , 2018, The Lancet. Oncology.

[5]  R. Mayer,et al.  Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. , 2018 .

[6]  D. McMillan,et al.  The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores , 2018, British Journal of Cancer.

[7]  C. Rosales.  Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? , 2018, Front. Physiol..

[8]  R. Kreienberg,et al.  Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. , 2017, Journal of geriatric oncology.

[9]  D. McMillan,et al.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis , 2017, Scientific Reports.

[10]  D. Cunningham,et al.  Rash, neutrophil-lymphocyte ratio (NLR) and survival in the REAL3 trial , 2017 .

[11]  J. Bruix,et al.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[12]  J. Soria,et al.  Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). , 2017, European journal of cancer.

[13]  C. Hurt,et al.  The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  S. Sleijfer,et al.  1502PEvolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials , 2017 .

[15]  N. Tunariu,et al.  346PPrognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in phase I (Ph1) trials: The Royal Marsden (RMH) Experience , 2017 .

[16]  B. Laird,et al.  The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. , 2017, Critical reviews in oncology/hematology.

[17]  H. Katayama,et al.  Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303) , 2017, International Journal of Clinical Oncology.

[18]  J. Bridgewater,et al.  Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study , 2017, Anti-cancer drugs.

[19]  G. Bodoky,et al.  The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/ , 2017 .

[20]  Daniel J Sargent,et al.  Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Hwang,et al.  Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710 , 2016, Cancer.

[22]  M. Chua,et al.  Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. , 2016, European Journal of Cancer.

[23]  H. Sorbye,et al.  Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer , 2016, Oncotarget.

[24]  V. Gebski,et al.  Is baseline neutrophil to lymphocyte ratio (NLR) an independent prognostic biomarker for progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC)? Analysis of the AGITG MAX study , 2016 .

[25]  V. Gebski,et al.  Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies , 2016 .

[26]  M. Hjermstad,et al.  Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Vasile,et al.  First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors , 2016, International journal of cancer.

[28]  E. Scarpi,et al.  Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer , 2016, Oncotarget.

[29]  D. Cunningham,et al.  Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Nemunaitis,et al.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Furuse,et al.  Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  L. Marchionni,et al.  Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents , 2015, Annals of Hematology.

[33]  J. Bono,et al.  Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  I. Tannock,et al.  Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Kaye,et al.  The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials , 2015, British Journal of Cancer.

[36]  N. Jamieson,et al.  nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial , 2015 .

[37]  Gregory R Pond,et al.  Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.

[38]  M. Oka,et al.  A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) , 2014, Journal of Translational Medicine.

[39]  P. Tassone,et al.  Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial , 2014, Journal of immunotherapy.

[40]  G. Pond,et al.  Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. , 2013, Clinical genitourinary cancer.

[41]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[42]  P. Fayers,et al.  Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System , 2013, Clinical Cancer Research.

[43]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[44]  V. Gebski,et al.  Markers of systemic inflammation predict survival in patients with advanced renal cell cancer , 2013, British Journal of Cancer.

[45]  E. Kvale,et al.  Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer , 2013, Cancer Chemotherapy and Pharmacology.

[46]  Heung Tae Kim,et al.  Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy , 2012, Journal of Cancer Research and Clinical Oncology.

[47]  N. Macdonald.  Terminology in cancer cachexia: importance and status , 2012, Current opinion in clinical nutrition and metabolic care.

[48]  S. Clarke,et al.  Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer , 2012, Supportive Care in Cancer.

[49]  K. Sikora,et al.  The economics of cancer care in the UK. , 2004, The Lancet. Oncology.